Total Payments
$139,035
2024 Payments
$5,219
Companies
39
Transactions
396
Medicare Patients
838
Medicare Billing
$62,944
Payment Breakdown by Category
Research$117,831 (84.7%)
Food & Beverage$7,860 (5.7%)
Travel$6,127 (4.4%)
Other$4,773 (3.4%)
Consulting$2,430 (1.7%)
Education$13.89 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $117,831 | 28 | 84.7% |
| Food and Beverage | $7,860 | 332 | 5.7% |
| Travel and Lodging | $6,127 | 28 | 4.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,773 | 4 | 3.4% |
| Consulting Fee | $2,430 | 3 | 1.7% |
| Education | $13.89 | 1 | 0.0% |
Payments by Type
Research
$117,831
28 transactions
General
$21,204
368 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lupin Inc. | $85,158 | 11 | $0 (2018) |
| Glenmark Pharmaceuticals Inc. | $20,080 | 9 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $5,949 | 99 | $0 (2023) |
| Acorda Therapeutics, Inc | $5,372 | 1 | $0 (2017) |
| Amphastar Pharmaceuticals, Inc. | $5,051 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,620 | 30 | $0 (2021) |
| Mylan Inc. | $2,490 | 2 | $0 (2020) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $2,115 | 1 | $0 (2017) |
| Allergan Inc. | $2,108 | 5 | $0 (2017) |
| AstraZeneca UK Limited | $1,985 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,219 | 2 | Amphastar Pharmaceuticals, Inc. ($5,051) |
| 2023 | $3,801 | 20 | AstraZeneca UK Limited ($1,985) |
| 2022 | $1,353 | 12 | AstraZeneca Pharmaceuticals LP ($1,206) |
| 2021 | $1,558 | 74 | AstraZeneca Pharmaceuticals LP ($383.89) |
| 2020 | $2,191 | 51 | Mylan Inc. ($1,245) |
| 2019 | $3,861 | 69 | AstraZeneca Pharmaceuticals LP ($1,806) |
| 2018 | $86,284 | 74 | Lupin Inc. ($85,158) |
| 2017 | $34,769 | 94 | Glenmark Pharmaceuticals Inc. ($20,080) |
All Payment Transactions
396 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/20/2024 | Amphastar Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $5,051.00 | Research |
| Study: General Consult | ||||||
| 02/23/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $168.13 | General |
| 07/13/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| 05/29/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| 04/14/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $432.90 | General |
| Category: Respiratory | ||||||
| 04/14/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $55.53 | General |
| Category: Respiratory | ||||||
| 04/14/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $40.64 | General |
| Category: Respiratory | ||||||
| 04/14/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: Respiratory | ||||||
| 04/14/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Respiratory | ||||||
| 04/13/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $203.17 | General |
| Category: Respiratory | ||||||
| 04/13/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $199.72 | General |
| Category: Respiratory | ||||||
| 04/13/2023 | AstraZeneca UK Limited | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $78.56 | General |
| Category: Respiratory | ||||||
| 03/22/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | Cash or cash equivalent | $528.00 | General |
| Category: Respiratory | ||||||
| 03/22/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | Cash or cash equivalent | $88.11 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $584.12 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $194.77 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $118.26 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $102.50 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $83.74 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $60.78 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Respiratory | ||||||
| 07/20/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $114.94 | General |
| Category: PRIMARY CARE | ||||||
| 05/02/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $9.63 | General |
| Category: PRIMARY CARE | ||||||
| 04/08/2022 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $504.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $82,658 | 10 |
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $20,080 | 9 |
| CVT-427 TRIP-PK-1041 | Acorda Therapeutics, Inc | $5,372 | 1 |
| General Consult | Amphastar Pharmaceuticals, Inc. | $5,051 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $2,500 | 1 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $876.00 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $876.00 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
| A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MCG INHALATION POWDER (CIPLA LTD., INDIA) WITH ADVAIR DISKUS 100/50 MCG (GLAXOSMITHKLINE, USA) IN ASTHMA PATIENTS. | CIPLA USA INC. | $62.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 9 | 391 | 1,449 | $100,638 | $31,511 |
| 2020 | 14 | 447 | 1,432 | $104,926 | $31,433 |
Total Patients
838
Total Services
2,881
Medicare Billing
$62,944
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 141 | 249 | $43,575 | $16,088 | 36.9% |
| 95165 | Preparation and provision of single or multiple antigens for allergen immunotherapy | Office | 2021 | 17 | 303 | $10,815 | $3,687 | 34.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 65 | 87 | $10,050 | $3,429 | 34.1% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 45 | 67 | $10,050 | $2,459 | 24.5% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 11 | 511 | $9,198 | $1,642 | 17.8% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 52 | 67 | $6,700 | $1,628 | 24.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 19 | 19 | $4,750 | $1,445 | 30.4% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2021 | 23 | 112 | $4,480 | $920.84 | 20.6% |
| 95115 | Injection of incremental dosages of allergen | Office | 2021 | 18 | 34 | $1,020 | $213.15 | 20.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 148 | 282 | $49,350 | $15,054 | 30.5% |
| 95165 | Preparation and provision of single or multiple antigens for allergen immunotherapy | Office | 2020 | 19 | 351 | $12,285 | $4,295 | 35.0% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2020 | 49 | 60 | $9,000 | $2,114 | 23.5% |
| 90653 | Vaccine for influenza for injection into muscle | Office | 2020 | 26 | 26 | $1,560 | $1,548 | 99.2% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 45 | 49 | $5,390 | $1,485 | 27.6% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 21 | 21 | $5,250 | $1,445 | 27.5% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2020 | 11 | 392 | $7,056 | $1,403 | 19.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 15 | $3,750 | $1,196 | 31.9% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2020 | 28 | 120 | $4,800 | $952.20 | 19.8% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 18 | 20 | $2,200 | $690.00 | 31.4% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2020 | 17 | 21 | $2,100 | $551.60 | 26.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 26 | 26 | $910.00 | $462.28 | 50.8% |
| 95115 | Injection of incremental dosages of allergen | Office | 2020 | 16 | 36 | $1,080 | $197.95 | 18.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 12 | 13 | $195.00 | $38.52 | 19.8% |
About Dr. S David Miller, MD
Dr. S David Miller, MD is a Allergy & Immunology healthcare provider based in North Dartmouth, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063471126.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. S David Miller, MD has received a total of $139,035 in payments from pharmaceutical and medical device companies, with $5,219 received in 2024. These payments were reported across 396 transactions from 39 companies. The most common payment nature is "" ($117,831).
As a Medicare-enrolled provider, Miller has provided services to 838 Medicare beneficiaries, totaling 2,881 services with total Medicare billing of $62,944. Data is available for 2 years (2020–2021), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Other Specialties Research Study
- Location North Dartmouth, MA
- Active Since 03/18/2006
- Last Updated 06/05/2013
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1063471126
Products in Payments
- TIOTROPIUM (Drug) $82,658
- BREZTRI (Drug) $2,991
- ADVAIR (Drug) $2,500
- Wixela Inhub (Drug) $2,490
- BEVESPI AEROSPHERE (Drug) $2,252
- SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE (Drug) $1,500
- QVM149 (Drug) $784.00
- NUCALA (Biological) $719.15
- UTIBRON (Drug) $672.86
- FEVIPIPRANT (Drug) $461.32
- TRELEGY ELLIPTA (Drug) $438.22
- CUVITRU (Biological) $297.50
- DUPIXENT (Biological) $279.72
- EUCRISA (Drug) $264.33
- NURTEC ODT (Drug) $246.23
- BREO (Drug) $212.51
- SPIRIVA RESPIMAT (Drug) $182.48
- Hizentra (Biological) $164.21
- FASENRA (Biological) $160.74
- XOLAIR (Biological) $151.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.